INCRELEX: payments to doctors
Payments that named INCRELEX as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $145K
- Providers
- 477
- Transactions
- 839
- Average per transaction
- $172
The per-transaction average — $172 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 477 providers the average total is $303, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Eton Pharmaceuticals, Inc. | $93,911 | 64.9% |
| Ipsen Biopharmaceuticals, Inc | $49,636 | 34.3% |
| Ipsen Biopharm Limited | $1,155 | 0.8% |